It was a good Monday morning for Endo Pharmaceutical Holdings Inc as their shares rise in the stock market after an analysts upgraded the stock predicting better third quarter and full year results for Endo. The shares of Endo Pharmaceutical had been down for last few days but the stocks jumped up substantially after the upgrade was done and it provided great boost to the Endo Pharmaceuticals to make sure that they perform better and come out with good results in the near future too.

Analysts John Newman changed his rating for the Endo Pharmaceutical Holdings to Outperform and had set the price target of $27 per share. Newman has further stated that Endo Pharmaceutical will surely exceed the profit expectations of Wall Street once their testosterone injection Fortesta will

...

Durect (DRRX) has had a rocky past six months. The immediate concern of biotech investors when they see a $2 stock is the cash position. Any stock trading at $2 must have significant cash burn concerns, right?Well, like Lee Corso says, "Not so fast my friend!" Durect exited the first quarter with $47.0 million in cash on hand and virtually no debt. Burn for the first quarter was only $5.7 million, and we expect that to decline in the coming quarters based on the March 2009 headcount reductions. Plus, we see several potential non-dilutive cash-raising opportunities in 2009 and 2010.Firstly, once Remoxy is finally approved, management will begin receiving payments from King Pharmaceuticals (KG). This will help reduce burn. However, management can sell the rights to these royalties for upfront cash if they choose.Second, management is going to re-partner the TRANSDUR-Sufentanil ...

For Immediate Release

Chicago, IL - May 8, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: General Motors Corp. (GM), Durect Corp. (DRRX), Endo Pharmaceuticals (ENDP), Onyx Pharmaceuticals (ONXX) and Supertex Inc. (SUPX).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Thursday's Analyst Blog:

GM Reports - Is Bankruptcy Near?

General Motors Corp. (GM) posted a reported net loss of $6.0 billion, including special items, or $9.78 per share in the first quarter of 2009. This compares with a reported net loss of $3.3 billion, or $5.80

...

We highlight Durect Corp. (DRRX), Endo Pharmaceuticals (ENDP) and King Pharmaceuticals, Inc. (KG).Durect Corp. (DRRX) has had a rocky past few months. The stock was hit harder than we expected in December 2008 when the FDA rejected the application on Remoxy. From our standpoint, the rejection of the NDA was not a surprise, but the reaction on Durect stock was.Nevertheless, we think the FDA's issues, most likely around the labeling, the abuse ability, and the risk management program, should only delay final approval by a year. We think that Remoxy will be on the market and generating royalties for Durect by the middle of 2010.The second big sell-off in the stock came in early March 2009 when Durect announced that Transdur development partner, Endo Pharmaceuticals (ENDP), was returning U.S. and Canadian rights to the product to Durect. The news ...

Highlighted stocks include Durect Corp. (DRRX), Endo Pharmaceuticals (ENDP) and King Pharmaceuticals (KG).Durect Corp. (DRRX) has had a rocky past few months. The stock was hit harder than we expected in December 2008 when the FDA rejected the application on Remoxy. From our standpoint, the rejection of the NDA was not a surprise, but the reaction for Durect stock was.Nevertheless, we think the FDA's issues -- most likely around the labeling, the abuse ability and the risk management program -- should only delay final approval by a year. We think that Remoxy will be on the market and generating royalties for Durect by the middle of 2010.The 2nd big sell-off in the stock came in early March 2009 when Durect announced that Transdur development partner, Endo Pharmaceuticals (ENDP), was returning U.S. and Canadian rights to the product to ...

Just two short weeks ago, we initiated coverage of Indevus Pharmaceuticals (IDEV) with a Buy rating and $6 price target. Paramount to our investment thesis was the eventual approval of Nebido in late calendar 2009.We were encouraged by the fact that management has come to an agreement with the FDA on the re-filing of the Nebido NDA, and believed that approval will be a transformational event for Indevus. We were also bullish on the rest of the pipeline.Endo Pharmaceuticals (ENDP) must agree, having just signed a definitive merger agreement with Indevus worth up to $7.50 per share to Indevus shareholders. We are advising clients to take the money as such, our rating is now Hold.Read the full analyst report on IDEV "IDEV" Free Stock Analysis: Buy? Sell? Hold?"ENDP" Free Stock Analysis: Buy? ...

Endo Pharmaceuticals (ENDP) to Acquire Indevus Pharmaceuticals (IDEV)In the first biotech deal of 2009, Endo Pharmaceuticals (ENDP) announced it has signed a definitive merger agreement with Indevus Pharmaceuticals (IDEV), whereby Endo will acquire 100% of the outstanding shares of Indevus for $370 million, or $4.50 per share, in upfront cash, with another potential $267 million, or $3.00 per share, in future consideration.The future potential cash to Indevus shareholders will come in the form of two contingent rights, one in the form of a $2.00 per share payment for the approval of Nebido, and the second $1.00 per share payment for the approval of octreotide implant.Indevus is currently trading at $5.24 per share, a 70% increase from the close yesterday. On December 26, 2008, we initiated coverage of Indevus at $2.71 per share with a Buy rating and $6.00 price ...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Alexza Pharmaceuticals Inc (ALXA) American River Bankshares (AMRB) Anesiva Inc (ANSV) Aon Corp (AOC) Arena Pharmaceuticals Inc (ARNA) Ariad Pharmaceuticals Inc (ARIA) Array BioPharma Inc (ARRY) athenahealth Inc (ATHN) Barloworld Ltd (BRRAY) Bio-Reference Laboratories Inc (BRLI) British Airways plc (BAIRY) CARBO Ceramics Inc (CRR) Cell Therapeutics Inc (CTIC) Chemed Corp (CHE) Corinthian Colleges Inc (COCO) Danaos Corp (DAC) Dialysis Corporation of America (DCAI) Diamond Mgt & Technology Consultants In (DTPI) Discovery Communications Inc (DISCB) DXP Enterprises Inc (DXPE) EarthLink Inc (ELNK) eDiets.com Inc (DIET) Elbit Systems Ltd (ESLT) Endo Pharmaceuticals (ENDP) Enterprise GP Holdings LP (EPE) ev3 Inc (EVVV) FiberTower Corp (FTWR) Flanders Corp (FLDR) GTx Inc ...

The way Endo Pharmaceuticals (Public, NASDAQ:ENDP) chart has been looking lately; you would think that it is the end. But it’s not December 21st 2012 yet people. There is still some life in Endo - read on to find out why it’s going back to $30 a share. Endo One year Chart: In April Endo released financial results for its first quarter under new leadership, and influences of the uprising by Endo's largest shareholder, D. E. Shaw Group (which owns just less than 10% of shares outstanding), are noticeable all over the company. In late February, D.E. Shaw was pushing Endo to make a huge share buyback. The campaigner and its allies got their way earlier this month (after ushering in a new Endo CEO in March), although Endo agreed to ...